Overview
Telbivudine is a synthetic thymidine nucleoside analogue developed specifically for antiviral therapy against hepatitis B virus (HBV). Approved by the FDA in 2006, it represents an important therapeutic option in the management of chronic HBV infection. As an L-nucleoside enantiomer, telbivudine exhibits selective inhibition of HBV DNA polymerase with minimal effects on human DNA polymerases. Its development marked a significant advancement in HBV treatment due to its potent viral suppression and relatively favorable resistance profile compared to earlier nucleoside analogues.
Physical and Chemical Properties
Telbivudine appears as a white crystalline powder with good solubility in aqueous solutions, which contributes to its bioavailability when formulated as oral tablets. The compound demonstrates stability under recommended storage conditions but may degrade upon prolonged exposure to moisture or light. Its molecular structure features a β-L-2'-deoxyribose sugar moiety, which distinguishes it from natural nucleosides and contributes to its antiviral specificity. The compound's logP value suggests moderate lipophilicity, influencing its pharmacokinetic properties and tissue distribution.
Main Applications
Telbivudine is indicated for the treatment of chronic hepatitis B in adults with evidence of viral replication and either elevated serum aminotransferases (ALT or AST) or histologically active disease. It is particularly effective against HBV genotypes B and C, which are prevalent in Asia. In clinical practice, telbivudine is used as monotherapy or in combination regimens, depending on patient factors and treatment guidelines. Its use has declined somewhat with the introduction of newer antivirals but remains relevant in specific clinical scenarios and certain healthcare systems due to cost considerations.
Safety and Storage
Proper storage of telbivudine requires refrigeration (2-8°C) in airtight containers with desiccants to maintain stability. The compound should be protected from light exposure to prevent photodegradation. From a safety perspective, healthcare providers must monitor patients for potential adverse effects, particularly myopathy and peripheral neuropathy. Laboratory personnel handling the raw compound should use appropriate personal protective equipment, including gloves and safety glasses, especially when working with powder formulations.
B2B Procurement Guide
Pharmaceutical manufacturers sourcing telbivudine should prioritize suppliers with demonstrated GMP compliance and proper documentation of synthesis pathways. Batch certificates should confirm high purity (>98%) and provide detailed impurity profiles. When evaluating suppliers, consider their track record in reliable delivery, cold chain management capabilities, and regulatory documentation support. Many buyers establish long-term contracts to ensure consistent supply, with price negotiations typically based on volume commitments and quality certifications.